PubMed Health⌕ Search

Biomedical subjects

H C Pitot

Publications and source records attributed to H C Pitot.

At least 109 records · Page 6Linked to original sources
PubMed1994

Multiple mechanisms are responsible for altered expression of gap junction genes during oncogenesis in rat liver.

Although several abnormalities in gap junction (GJ) structure and/or function have been described in neoplasms, the molecular mechanisms responsible for many of the alterations remain unknown. The identification of a family of GJ proteins, termed connexins, prompted this study of connexin32 (Cx32), connexin26 (Cx26) and connexin43 (Cx43) expression during rat hepatocarcinogenesis. Using antibody, cDNA and cRNA probes, we investigated connexin mRNA and protein expression in preneoplastic and neoplastic rat livers. In normal liver, Cx32 is expressed in hepatocytes throughout the hepatic acinus, Cx26 is restricted to periportal hepatocytes, and Cx43 is expressed by mesothelial cells forming Glisson's capsule. Most preneoplastic altered hepatic foci generated by diethylnitrosamine (DEN) initiation and either phenobarbital (PB) or 2,3,7,8-dichlorodibenzo-p-dioxin (TCDD) promotion exhibited decreased Cx32 or increased Cx26 staining. Foci from either protocol failed to display Cx43 immunoreactivity. In the majority of PB-promoted foci, Cx32 immunoreactivity decreased independently of changes in mRNA abundance. Continuous thymidine labeling, following cessation of PB promotion, showed that downregulation of Cx32 staining is reversible in foci that are promoter-dependent for growth, but irreversible in lesions that are promoter-independent for growth. Hepatic neoplasms from rats initiated with DEN and promoted with PB or TCDD also displayed modified connexin expression. While all 24 neoplasms studied were deficient in normal punctate Cx32 and Cx26 staining, altered cellular localization of these proteins was apparent in some tumors. Immunoblotting of crude tissue extracts revealed that neoplasms with disordered Cx32 staining showed immunoreactive bands with altered electrophoretic mobility. These observations show that hepatomas may downregulate Cx32 expression through changes in the primary structure of Cx32 or by post-translational modifications. Northern blotting of total tumor mRNAs failed to demonstrate consistent changes in the abundance of Cx32, Cx26 or Cx43 transcripts. Some tumors expressed steady-state transcripts without observable immunoreactivity, indicating that some hepatomas downregulate connexin immunoreactivity independently of mRNA abundance. Increased levels of Cx43 mRNA and protein were found in several neoplasms, but immunostaining was always localized to nonparenchymal cells. Areas of bile duct proliferation and cholangiomas displayed Cx43 staining, whereas, cholangiocarcinomas were deficient in immunoreactivity. These findings show that alterations in the expression of connexins, by either downregulation or differential induction, represent common modifications during hepatocarcinogenesis. Although our results imply that connexins represent useful markers for the boundary between tumor promotion and progression, preneoplastic and neoplastic rat hepatocytes fail to use a common mechanism to modify connexin expression.

Animals↗
PubMed1994

Transgenic hepatocarcinogenesis in the rat.

Although transgenic hepatocarcinogenesis has been accomplished in the mouse with a number of genetic constructs targeting the oncogene to expression primarily in the liver, no example of this process has yet been developed in the rat. Because our understanding of the multistage nature of hepatocarcinogenesis is most advanced in the rat, we have developed a strain of transgenic rats carrying the promoter-enhancer sequences of the mouse albumin gene linked 5' to the simian virus-40 T antigen gene. A line of transgenic rats bearing this transgene has been developed from a single founder female. Five to six copies of the transgene, possibly in tandem, occur within the genome of the transgenic animals, which are maintained by heterozygous matings. Livers of transgenic animals are histologically normal after weaning; at 2 months of age, small foci of vacuolated cells appear in this organ. By 4 months of age, all animals exhibit focal lesions and nodules consisting primarily of small basophilic cells, many of which exhibit considerable cytoplasmic vacuolization. Mating of animals each bearing the transgene results in rats with a demyelinating condition that develops acutely in pregnant females and more chronically in males. Ultrastructural studies of these cells indicate that the vacuoles contain substantial amounts of glycogen, with the cells resembling hepatoblasts. Malignant neoplasms with both a glandular and a hepatoblastoma/hepatocellular carcinoma pattern arise from the nodules. Enzyme and immunohistochemical studies of all lesions reveal many similarities in gene expression to comparable lesions in rats subjected to chemically induced hepatocarcinogenesis, with certain exceptions. The placental form of glutathione-S-transferase is absent from all lesions in the transgenic animal, as is the expression of connexin 32. A significant number of lesions express serum albumin, and many, but not all, exhibit the T antigen. Lesions expressing the T antigen also contain stainable amounts of the p53 gene product; by contrast, normal hepatocytes express only very low levels of the T antigen within their nuclei and no demonstrable p53. All of the animals develop hepatic lesions, and approximately one-third also develop adenomas and carcinomas derived from the islet cells of the pancreas. Although there are differences in the morphology, biology, and genetic expression in early and late hepatic lesions in this strain of transgenic rat, many similarities also occur, making this a potential model system with which to study the interactions of environmental factors with a genetic program for hepatocarcinogenesis.

Animals↗
PubMed1993

Effect of the peroxisome proliferator perfluorodecanoic acid on the promotion of two-stage hepatocarcinogenesis in rats.

This study was conducted to determine if the peroxisome proliferator perfluorodecanoic acid (PFDA) has promoting activity in two-stage hepatocarcinogenesis. Because PFDA is a non-competitive inhibitor of the peroxisomal bifunctional enzyme and thus inhibits the peroxisomal beta pathway, we hypothesized that PFDA may not have promoting activity as do other peroxisome proliferators, because hydrogen peroxide production is inhibited. Twenty-four hours after partial hepatectomy, female Sprague-Dawley rats were given an initiating dose of 10 mg/kg diethylnitrosamine by gavage. The rats were divided into five groups that received monthly i.p. injections of 0.0, 0.05, 0.50 or 5.0 mg/kg PFDA in corn oil or were placed on diets that contained either 0.01% ciprofibrate or 0.05% phenobarbital for 9 or 18 months. Both ciprofibrate and the highest dose of PFDA increased the activity of the peroxisomal enzyme fatty acyl CoA oxidase. PFDA treatment did not increase the tumor incidence or the number of altered hepatic foci at 9 or 18 months, although the mean volume of foci was increased at 9 months. Ciprofibrate increased the incidence of hepatocellular carcinomas at 18 months but did not increase the number or volume of altered hepatic foci at 9 or 18 months. Phenobarbital increased the number and volume of foci but did not influence the tumor incidence. The results of this investigation indicate that PFDA is not a promoter of hepatocarcinogenesis.

Adenosine Triphosphatases↗
PubMed1993

The molecular biology of carcinogenesis.

Carcinogenesis may result from the action of any one or a combination of chemical, physical, biologic, and/or genetic insults to cells. The process of carcinogenesis may be divided into at least three stages: initiation, promotion, and progression. The first stage of carcinogenesis, initiation, results from an irreversible genetic alteration, most likely one or more simple mutations, transversions, transitions, and/or small deletions in DNA. The reversible stage of promotion does not involve changes in the structure of DNA but rather in the expression of the genome mediated through promoter-receptor interactions. The final irreversible stage of progression is characterized by karyotypic instability and malignant growth. Critical molecular targets during the stages of carcinogenesis include proto-oncogenes, cellular oncogenes, and tumor suppressor genes, alterations in both alleles of the latter being found only in the stage of progression. Although many of these critical target genes have been identified, the ultimate number and characteristics of molecular alterations that define neoplasia have not been elucidated.

Animals↗
PubMed1993

Effect of age on the formation of small-cell colonies in cultures of primary rat hepatocytes.

The proliferation of primary cultured rat hepatocytes was observed in serum-free modified Dulbecco's modified Eagle's medium supplemented with 10 mM nicotinamide and 10 ng/ml of epidermal growth factor. These proliferating cells were mainly mononucleate and formed small-cell colonies after Day 4. The small cells in focal colonies were surrounded by typical hepatocytes and were stained immunocytochemically with anti-rat albumin and anti-cytokeratin 8 antibodies. This suggests that the cells in the small-cell colonies were derived from hepatocytes. The frequency of appearance of small-cell colonies with age was examined by the use of primary cultured hepatocytes isolated from the livers of rats between the ages of 3 wk and 90 wk. In the cells from 4- to 5-wk-old rats, about 58 colonies per 1000 attached cells appeared 144 h after plating; the number of colonies rapidly decreased to about 25 in 6- to 8-wk-old rats. In adult rats, about 17 colonies were seen, and only about five colonies were observed in rats more than 80 wk old.

Aging↗
PubMed1993

Oxaloacetate induces DNA synthesis and mitosis in primary cultured rat hepatocytes in the absence of EGF.

Oxaloacetate (OA), one of the substrates in the tricarboxylic acid (TCA) cycle, was found to induce proliferation of primary cultured rat hepatocytes. During the 5 days of culture in a serum-free medium with 30 mM OA, hepatocyte DNA synthesis had been induced to the same degree as by culturing with 10 ng/ml epidermal growth factor (EGF). A 3% mitotic index was observed in OA-treated cells 60-70 hr after plating. The OA-induced DNA synthesis was inhibited by transforming growth factor-beta in a dose-dependent manner and was abolished by 10 mM hydroxyurea. OA and EGF induced DNA synthesis synergistically with > 91% of the nuclei of the cells entering S phase at 48-72 hr in culture. Among other substrates in the TCA cycle, pyruvate, lactate, alpha-ketoglutarate, succinate, fumarate, and malate at equimolar concentrations to that of OA also induced DNA synthesis. However, their activities were about half or less than that with OA. These results show that OA is a hepatocyte mitogen in vitro.

Animals↗
PubMed1993

Variability in the oral bioavailability of all-trans-retinoic acid.

BACKGROUND: Orally administered all-trans-retinoic acid (all-trans-RA) can induce complete remission in a high proportion of patients with acute promyelocytic leukemia. A previous pharmacokinetic study in patients with acute promyelocytic leukemia raised the possibility that the absorption of orally administered all-trans-RA is a saturable process that would have significant clinical impact on dosing strategies. PURPOSE: This study was specifically designed to examine the saturability of all-trans-RA absorption by measuring the effect of doubling the oral dose of all-trans-RA on plasma drug concentration in patients receiving long-term oral therapy. METHODS: Six patients with solid tumors received oral doses of 10-mg gelatin capsules of all-trans-RA. Patients were studied on 2 consecutive days after they received 28 days of all-trans-RA administered as two daily 78-mg/m2 doses. The study assigned the patients to two groups. Three patients took a 156-mg/m2 dose on day 28 and a 78-mg/m2 dose on day 29; the other three patients took the lower dose on day 28 and the double dose on day 29. Blood samples for the determination of all-trans-RA plasma concentration were obtained at 30-minute intervals starting just prior to drug administration and continuing for a total of 7 hours. The plasma concentration of all-trans-RA was measured by high-performance liquid chromatography. RESULTS: Plasma concentrations following an oral dose of all-trans-RA were highly variable, with peak concentrations ranging from 0.07 to 1.2 microM for the 78-mg/m2 dose level. Doubling the dose from 78 to 156 mg/m2 increased plasma concentration in all six patients, but the increase was unpredictable and not related to dose, ranging from less than a 1.2-fold to more than a 10-fold increase. CONCLUSION: The current study does not support the hypothesis that the gastrointestinal absorption of all-trans-RA involves a saturable process but instead suggests that absorption is highly variable among patients. This wide interpatient variability suggests that pharmacokinetic drug monitoring may have an important role in the management of patients receiving all-trans-RA.

Adenocarcinoma↗
PubMed1993

Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice.

Certain "high-risk" anogenital human papillomaviruses (HPVs) have been associated with the majority of human cervical carcinomas. In these cancers, two papillomaviral genes, E6 and E7, are commonly expressed. In this study we provide evidence that expression of the E6 and E7 genes from the high-risk HPV-16 in the skin of transgenic mice potentiated the development of preneoplastic lesions, and a high percentage of these epidermal lesions subsequently developed into locally invasive cancers. High levels of E6/E7 expression were found in these tumors relative to the preneoplastic lesions, and expression was localized to the proliferating, poorly differentiated epidermal cells. Also, the p53 and Rb genes were found to be intact, not mutationally inactivated, in representative skin tumors. These findings demonstrate that the E6 and E7 genes from a papillomavirus etiologically associated with human cervical cancer can contribute to the development of epidermal cancers in an animal model.

Animals↗
PubMed1993

Organization and characterization of the rat class 3 aldehyde dehydrogenase gene.

Expression of class 3 aldehyde dehydrogenase (ALDH-3) is constitutive or inducible, depending on the tissue. ALDH-3 induction occurs both during neoplastic development and after exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In order to study the regulation of ALDH-3 gene expression, ALDH-3 genomic sequences have been obtained from normal rat genomic DNA. Two overlapping genomic fragments (ALDH-UTR-1 and ALDH-NL2) contain the entire ALDH-3 gene along with considerable 5'- and 3'-flanking sequences. The rat ALDH-3 gene spans approximately 9 kilobases in length and consists of eleven exons; ten coding and one 5'-noncoding. The region 5' to exon one contains several putative transcription factor binding elements which may be important in the TCDD inducibility of this gene. These include a xenobiotic response element (XRE), a drug response element (DRE), LAP and Ap1 binding sites, and one Sp1 site. There are considerable differences in organization between the rat and human class 3 ALDH genes. Primer extension and RNase protection analysis indicate that both basal and TCDD-inducible expression of the ALDH-3 gene utilize the same multiple transcription start sites.

Aldehyde Dehydrogenase↗
PubMed1993

The effect of the dose of diethylnitrosamine on the initiation of altered hepatic foci in neonatal female rats.

The dose-response characteristics of initiation of hepatocarcinogenesis by diethylnitrosamine (DEN) was investigated in the neonatal female rat by means of the quantitative stereologic estimation of altered hepatic foci (AHF) expressing multiple markers. At 5 days of age, female Sprague-Dawley rats were given a single i.p. dose of DEN (0.1-30 mg/kg body wt) or the vehicle (trioctanoin). The semisynthetic AIN-76A diet was provided to half of the rats in each treatment group, while the remainder received this diet containing 500 mg phenobarbital (PB)/kg for 8 months from weaning until the animals were killed. To ascertain more exactly the dose-response relationship for initiation by DEN, the number, volume percentage and phenotypes of the resulting AHF were determined by quantitative stereological analysis on serial sections of frozen tissue, each stained for one of four markers of preneoplasia. A linear relationship was observed between the dose of DEN (0-30 mg/kg) and the number and volume percentage of AHF detected, with each single marker or the total number of AHF detected when the placental isozyme of glutathione S transferase, gamma-glutamyl transpeptidase (GGT), canalicular adenosine triphosphatase, or glucose-6-phosphatase was used as the marker. For each dose, PB administration increased the number and volume of AHF scored compared with similarly initiated rats that did not receive a promoting stimulus. This was, in part, owing to enhanced GGT expression in AHF with PB administration. Promotion by PB resulted in a distribution of AHF phenotypes altered from that observed in rats not receiving PB. Initiation of AHF in neonatal female rats by DEN was linear with doses from 0 to 30 mg/kg for all four of the phenotypic markers employed. In addition, while PB administration stimulated the growth of all AHF phenotypes, the growth of a subset of AHF that expressed the widest variation in preneoplastic markers was specifically enhanced by PB administration.

Animals↗
PubMed1993

Comparison of hepatocyte phenotypes at the glutathione transferase and albumin loci in Sprague-Dawley and Nagase analbuminemic rats and F1 progeny after initiation and promotion.

Hepatocarcinogenesis was examined in an initiation--promotion protocol with a single initiating dose of 7,12-dimethylbenz[a]anthracene (DMBA) followed by promotion with phenobarbital (PB) in the Nagase analbuminemic rat (NA), the Sprague-Dawley rat (SD) and their F1 crosses. All rats received a 70% partial hepatectomy, followed at 24 h by 30 mg DMBA/kg body wt or the solvent. After a 2 week recovery following surgery, half of the solvent control and initiated groups received either basal diet or promotion with 0.05% PB mixed into the basal NIH-07 diet. After 12 weeks of promotion, the rats were killed and the livers perfused and fixed in situ with paraformaldehyde. Liver slices were paraffin embedded and stained for the placental isozyme of glutathione S-transferase (PGST). The number of altered hepatic foci (AHF) expressing PGST per liver was determined by quantitative stereology and used as an endpoint for comparison of initiation in the rat strains. The NA rat had a lower response to this initiation-promotion protocol than did the SD rat. The F1 progeny of the male NA and female SD rats were more similar to the NA parent in their responsiveness to initiation, whereas the F1 progeny of the female NA and male SD were similar to the SD parent in this respect. Putative mutagenesis and carcinogenesis were examined in the F1 progeny of the female NA and male SD rat. In these rats, serial liver sections were stained either for albumin to detect putative mutations at that locus, or PGST to identify putatively initiated hepatocytes. In the NA/SD F1, the number of single hepatocytes with a putative mutation at the albumin locus was the same (3.7 x 10(5)/liver) as those expressing a common marker of preneoplasia (PGST). The number of AHF expressing PGST was approximately 5% that of the single cells exhibiting an altered expression of albumin or PGST, indicating a possible quantitative correlation between initiation and mutation in vivo when individual hepatocytes with altered gene expression were counted. These studies also suggest that only a subpopulation of the putatively initiated hepatocytes expands clonally in the presence of the promoting agent, PB. The progeny of the female NA rat crossed with the SD male rat appears to provide a useful model in which to compare mutation and carcinogenesis simultaneously in vivo.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1993

Quantitative comparison of initiation and mutation phenotypes in hepatocytes of the analbuminemic rat.

The potential relationship between mutagenesis and carcinogenesis has been examined in the Nagase analbuminemic rat treated with a single dose of benzo[a]pyrene, an incomplete liver carcinogen. The apparent mutation rate at the albumin locus was calculated by determining the number of hepatocytes expressing a cross-reactive product of albumin in analbuminemic rats treated with benzo[a]pyrene. The rate of initiation, the first stage in carcinogenesis, was determined by assessing the number of hepatocytes expressing the placental isozyme of glutathione S-transferase (PGST) after administration of benzo[a]pyrene. Since the expression of PGST may represent hepatocellular changes independent of initiation, promotion with phenobarbital was employed to clonally expand those putatively initiated hepatocytes expressing PGST. With immunohistochemical measures to assess changes in albumin expression, a threefold increase in the number of hepatocytes expressing albumin was detected after administration of benzo[a]pyrene in Nagase analbuminemic rats. A more than five-fold increase in altered hepatic foci (AHF) exhibiting increased PGST expression was observed in animals given benzo[a]pyrene treatment followed by phenobarbital, compared with those given benzo[a]pyrene alone. The number of albumin-expressing single hepatocytes detected was of the same order of magnitude as the number of individual hepatocytes and AHF expressing PGST, suggesting that similar events may be involved in their formation. Since 3 x 10(6) single hepatocytes expressing albumin were found in the analbuminemic rat liver after a single administration of benzo[a]pyrene, while less than 2 x 10(4) AHF expressing PGST were observed, formation of individual hepatocytes expressing albumin was a far more frequent event than clonal expansion of initiated hepatocytes in the Nagase analbuminemic rat. However, the number of loci of PGST expression including AHF and single hepatocytes is comparable to that of single hepatocytes expressing albumin.

Albumins↗
PubMed1993

Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

BACKGROUND: The carcinoid syndrome is a rare cause of acquired valvular heart disease. Although the typical echocardiographic features of carcinoid heart disease are well recognized, this large series provides new information about unusual manifestations of the disease as well as the role of Doppler echocardiography. METHODS AND RESULTS: Between 1980 and 1989, 132 patients with carcinoid syndrome underwent echocardiographic study. The echocardiographic, Doppler, and clinical features of the 74 patients (56%) with echocardiographic evidence of carcinoid heart disease are described. Among these patients, 97% had shortened, thickened tricuspid leaflets. Tricuspid regurgitation was present in all 69 patients with carcinoid heart disease who underwent Doppler examination, and it was of moderate or severe degree in 62 patients (90%). Severe tricuspid regurgitation was characterized by a dagger-shaped Doppler spectral profile with an early peak pressure and rapid decline. The pressure half-time was prolonged (mean, 116 msec), which is consistent with associated tricuspid stenosis. The pulmonary valve appeared thickened, retracted, and immobile in 36 patients (49%) and was diminutive to the extent of not being visualized in an additional 29 patients (39%). Among the 47 patients who underwent Doppler evaluation of the pulmonary valve, regurgitation was present in 81%, and stenosis was present in 53%. Left-sided valvular involvement was present in five patients (7%), four of whom had patent foramen ovale or carcinoid tumor involving the lung. Previously undescribed myocardial metastases were present in three patients (4%) and were confirmed by biopsy in each case. Small pericardial effusions were present in 10 patients (14%). Patients with and without echocardiographic evidence of carcinoid heart disease did not differ with regard to sex, age, location of the primary tumor, duration of diagnosis, or duration of symptoms of carcinoid syndrome. However, the mean pretreatment level of urinary 5-hydroxyindoleacetic acid was higher in patients with carcinoid heart disease than in patients without carcinoid heart disease (270 versus 131 mg/24 hrs, p < 0.001). The symptom of dyspnea was more prevalent among patients with carcinoid heart disease than in patients without the disease (54% versus 27%, p = 0.003); as expected, heart murmurs were also noted more frequently in patients with disease (92% versus 43%, p < 0.0001). Treatment regimens and response to therapy were similar in the two groups. Survival of patients with echocardiographic evidence of carcinoid heart disease was reduced compared with those without cardiac involvement (p = 0.0003). ECG and chest roentgenographic findings in patients with carcinoid heart disease were nonspecific. CONCLUSIONS: The broad spectrum of carcinoid heart disease is detailed in this large series. This includes not only right-sided valvular lesions but also left-sided involvement, pericardial effusion, and myocardial metastases.

Carcinoid Heart Disease↗
PubMed1993

The initiation-promotion-progression model of rat hepatocarcinogenesis.

Carcinogenesis is a multistage process consisting of the three distinct stages: initiation, promotion, and progression. The initiation-promotion-progression (IPP) protocol models these stages and establishes a method whereby agents that possess a carcinogenic risk can be classified as acting primarily at any one or combination of these stages. In one hepatocarcinogenesis IPP protocol, rats were initiated with 10 mg of diethylnitrosamine/kg body wt at 5 days of age, started on the promoting agent phenobarbital at weaning, subjected to a 70% partial hepatectomy at 6 months, and, at the peak of proliferation, given a putative progressor agent, ethylnitrosourea ([ENU] 100 mg/kg, ip) or hydroxy-urea ([HU] 3 x 150 mg/kg, ip). Administration of the promoting agent was discontinued after the progressor agent was given, and the rats were sacrificed 6 months later. The number and volume fraction of promoter-independent (growth in the absence of the promoting agent) altered hepatic foci (AHF) were then determined by quantitative stereology. The number of such AHF increased with either ENU or HU treatment compared with animals not given a progressor agent. In addition, hepatocytes isolated from animals subjected to an IPP regimen with ENU as the progressor agent exhibited a greater degree of chromosomal breakage and aneuploidy than animals not given a second initiator. A variation of this model, in which the promoting agent was maintained after administration of the progressor agent, was examined. In this IPP model, the number of heterogeneous AHF (foci-in-foci) increased after application of the progressor agent (ENU or HU). An increased incidence of hepatocellular carcinoma was also observed in animals subjected to the IPP protocol when promotion was maintained until sacrifice. Thus, the characteristics of progression--increased chromosomal damage, aneuploidy, growth of AHF in the absence of continued tumor promotion, the presence of foci-in-foci, and an increased incidence of malignant neoplasia--have been used as end points for the demonstration of progressor activity by ENU. In addition, the potential progressor activity of HU and benzene has been demonstrated with the IPP model of rat hepatocarcinogenesis.

Adenosine Triphosphatases↗